Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Drug |
Pharmacologic Class |
Indication |
More Information |
| Dermatological Disorders | |||
| Zelsuvmi (berdazimer topical gel) | Nitric oxide releasing topical antiviral | Treatment of molluscum contagiosum in adults and pediatric patients 1 year of age and older. | Zelsuvmi Approved for Topical Treatment of Molluscum Contagiosum |
| Gastrohepatic Disorders | |||
| Dupixent (dupilumab) | Interleukin-4 receptor alpha antagonist | Treatment of pediatric patients aged 1 to 11 years, weighing at least 15kg, with eosinophilic esophagitis. | Dupixent Approved for Pediatric Eosinophilic Esophagitis |
| Hematological Disorders | |||
| Casgevy (exagamglogene autotemcel) | CRISPR/Cas9 gene-edited therapy | Treatment of patients aged 12 years and older with transfusion-dependent β-thalassemia. | Gene Therapy Casgevy Approved for Transfusion-Dependent Beta Thalassemia |
| Neurologic Disorders | |||
| Gammagard Liquid (immune globulin infusion 10%) | Immune globulin | To improve neuromuscular disability and impairment in adult patients with chronic inflammatory demyelinating polyneuropathy. | Gammagard Liquid Approved for Chronic Inflammatory Demyelinating Polyneuropathy |
| HyQvia (immune globulin infusion 10% [human] with recombinant human hyaluronidase) | Immune globulin + recombinant human hyaluronidase | Treatment of chronic inflammatory demyelinating polyneuropathy as maintenance therapy to prevent relapse of neuromuscular disability and impairment in adults. | HyQvia Approved for Chronic Inflammatory Demyelinating Polyneuropathy |
| Oncology | |||
| Balversa (erdafitinib) |
Kinase inhibitor
|
Treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations whose disease has progressed on or after at least 1 line of prior systemic therapy. | Balversa Gets Full Approval for Advanced or Metastatic Urothelial Carcinoma |
| Keytruda (pembrolizumab) |
Programmed death receptor-1 blocking antibody
|
In combination with chemoradiotherapy for the treatment of patients with FIGO (International Federation of Gynecology and Obstetrics) 2014 Stage III-IVA cervical cancer. | Keytruda Plus Chemoradiotherapy Approved for FIGO 2014 Stage III-IVA Cervical Cancer |
Please login or register first to view this content.
